- 73% ORR in 11 patients at 800 mg dose.
- Median DOR 9 months, median PFS 11 months.
- 90% CRS (all Grade 1-2), 21% serious TEAEs.
- Regeneron enrolling registrational trial and planning Phase 3.
- Regeneron presented first clinical data for ubamatamab in low-grade serous ovarian cancer (LGSOC) at IGCS 2026. In 11 patients treated at 800 mg, the objective response rate was 73%, median duration of response 9 months, and median progression-free survival 11 months. Safety showed 90% cytokine release syndrome (all Grade 1-2) and 21% serious treatment-emergent adverse events.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card